Heart failure & cardiomyopathies
The HFpEF-ABA score predicts adverse cardiac remodelling and incident heart failure: a UK biobank study
- community-based cohort
- dual validation approach combining cardiac magnetic resonance phenotyping and long-term outcome prediction
+1 more
- dual validation approach combining cardiac magnetic resonance phenotyping and long-term outcome prediction
Authors' conclusion
The HFpEF-ABA score demonstrates significant prognostic value for identifying individuals at high risk for incident heart failure and is associated with adverse cardiac remodelling and subclinical cardiac changes. These findings support repositioning the score from a diagnostic aid to a population-level screening instrument, supporting earlier identification of high-risk individuals before overt clinical heart failure develops.
Study context
- Population
- UK Biobank participants without baseline heart failureUK Biobank participants without baseline heart failure, cardiac magnetic resonance subcohort 65,293 · cardiac magnetic resonance subcohort 65,293
- Participants
- 416,374 participants
- Exposure
- HFpEF-ABA score risk strata
Main finding
As reported in the abstract
LA ejection fraction
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| incident heart failure hospitalization · median follow-up of 14.9 years | 6.44 (5.86–7.08) | P < 0.001 | |
| 0.10.31310Hazard ratio (log scale) |
composite outcome
- 3.5-fold increased risk of the composite outcome
- P < 0.001
discrimination
- The score demonstrated robust discrimination, outperforming its individual components.
Original publication
The HFpEF-ABA score predicts adverse cardiac remodelling and incident heart failure: a UK biobank study. ESC Heart Fail. Published 7 July 2026. doi:10.1093/eschf/xvag171
Summarised from the published abstract; every number is checked against it